A5025544634- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk
- COVID-19 Clinical Research Studies
- Family Caregiving in Mental Illness
- Immunodeficiency and Autoimmune Disorders
- Comparative International Legal Studies
- Sexuality, Behavior, and Technology
- HIV/AIDS oral health manifestations
- Pharmacological Effects and Toxicity Studies
- Data Management and Algorithms
- Data Mining Algorithms and Applications
- Maternal Mental Health During Pregnancy and Postpartum
- Sepsis Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Antifungal resistance and susceptibility
- Algorithms and Data Compression
- Long-Term Effects of COVID-19
- Fungal Infections and Studies
Hospital Universitario La Paz
2013-2025
Centro de Investigación Biomédica en Red
2022-2025
Instituto de Salud Carlos III
2022-2025
Hospital La Paz Institute for Health Research
2022-2023
Although anxiety, depression and insomnia in people with HIV (PWH) are prevalent have a major impact on clinical outcomes quality of life, physicians fail to evaluate them routinely. The CONECTAR Project [Neuropsychiatric Comorbidity (NPC): Key Antiretroviral Treatment] aimed improve NPC care PWH Spain by upskilling healthcare professionals (HCPs). A group HCPs developed training programme, supported national international guidelines, expertise detecting managing NPCs PWH. programme was...
Abstract Background We previously described the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a switch strategy in real life people with HIV (PWH) at 48 weeks. did not find that previous nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) had an impact on efficacy. Herein we report response rates after 3 years follow-up. Methods This retrospective review comprised PWH who were treatment experienced and switched to B/F/TAF...
Dolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a switching strategy in virologically suppressed people with HIV (PWH). As this was introduced relatively recently, real-world, long-term durability studies are lacking.We performed retrospective review of treatment-experienced patients who started DTG + 3TC cohort PWH. HIV-RNA <50 copies/mL analysed at 144 weeks an intention-to-treat (ITT) analysis (missing = failure) and per-protocol (PP) (patients missing data or...
In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals and without archived resistance-associated mutations (RAMs) detected next-generation sequencing (NGS) but evidence RAMs baseline proviral DNA population sequencing.To present 96 week results from ART-PRO.Open-label, single-arm trial. At baseline, all participants switched to lamivudine. Participants excluded if genotyping RAMs. To detect...
Introduction: Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-world data are also scarce. Methods: Retrospective review treatment-experienced patients who started B/F/TAF a PWH. HIV-RNA less than 50 copies/ml was analyzed at 48 weeks an intention-to-treat (ITT)...
Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experiencing insomnia due to dolutegravir-related neurotoxicity is well founded upon evidence, there a lack of proof regard the outcome stopping dolutegravir-based ART without but reporting poor sleep quality.This randomized, multicenter, open-label study evaluate reversibility patient-reported disturbances patients on dolutegravir/lamivudine/abacavir after darunavir/cobicistat/emtricitabine/tenofovir...
Background: Sexualized drug use (SDU) has become a public health concern in recent years. This study aimed to estimate the prevalence of SDU gay, bisexual, and other men who have sex with living HIV (HIV + GBMSM) Madrid during 2019/2020 compare it data from 2016/2017 order detect changes patterns. Methods: We analyzed frequency sample GBMSM attending clinics, participated an anonymous online survey regarding sexual behavior recreational use. The association between SDU, risk behaviors, STIs...
A better understanding of the evolution cirrhosis after hepatitis C virus (HCV) clearance is essential since reversal liver injury may not happen. We aimed to assess plasma metabolites direct-acting antivirals (DAAs) therapy and their association with disease scores in HIV/HCV-coinfected patients advanced HCV-related cirrhosis.We performed a prospective study 49 cirrhotic who started DAAs therapy. Data samples were collected at baseline 36 weeks SVR. Metabolomics analysis was carried out...
Dolutegravir + rilpivirine (DTG RPV) is an effective antiretroviral therapy regimen approved in clinical guidelines as a switch for virologically suppressed people with HIV. Our study aimed to compare the effectiveness and tolerability of DTG RPV women men real-world practice.
Abstract Background Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy first-line antiretroviral regimens currently recommended worldwide. Continued surveillance transmitted drug (TDR) is thus warranted. Objectives We evaluated rates and effects on virological outcomes TDR a 96 week prospective multicentre cohort study ART-naive HIV-1-infected subjects initiating INSTI-based ART Spain between April 2015...
Abstract Introduction The use of tenofovir alafenamide (TAF) has been associated with increased cholesterol and body weight. Real‐life data on the metabolic effects switching from a TAF‐based triple regimen to dolutegravir (DTG)‐based two‐drug (2‐DR) are scarce. Methods A retrospective cohort study patients who have switched 2‐DR [DTG‐lamivudine (DTG‐3TC) or DTG‐ rilpivirine (DTG‐RPV]) at least 6 months follow‐up. primary endpoint was absolute change in lipid fractions months. Secondary...
Background Recent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) hepatitis B (HBV) in Europe are lacking. Aim Leveraged a study designed to assess HIV/HCV prevalence, we assessed HIV/HBV Spain 2018 compared results five similar studies performed since 2002. Methods This cross-sectional was carried out 43 centres, patients were selected using simple random sampling. The reference population comprised 40,322 sample size 1,690 patients. Results...
Here, we aim to describe mental health (MH) in a cohort of children, adolescents, and young adults living with perinatally acquired HIV (PHIV) Spain explore the treatment gap for disorders. We also analyze potential association between MH issues psychosocial risk factors (PSRFs) identify management priorities. conducted descriptive transversal study that included all cases PHIV under follow-up reference hospital Madrid. The patients undergoing pediatric outpatient clinic youths transferred...
Since the introduction of modern antiretroviral treatment for HIV and hepatitis C virus (HCV), pattern autoimmune diseases (ADs) in people living with (PWH) might have changed. This is a retrospective study cohort 5,665 PWH at Clinic Hospital Universitario La Paz (Spain) to estimate prevalence ADs from January 1990 June 2020. We divided timeline into four periods: <1996, 1996-2006, 2006-2015, 2015-2020. In total 369 participants were diagnosed least one AD, 5.3% (95% confidence interval...
Background: This study aimed to estimate the prevalence of sexualized drug use (SDU) in gay, bisexual, and other men who have sex with living HIV (HIV+GBMSM) Madrid during 2019/2020 compare it data from 2016/2017. Methods: We analysed frequency SDU a sample HIV+GBMSM attending clinics, participated an anonymous online survey regarding sexual behaviour recreational use. The association between SDU, risk behaviours, STIs was evaluated. methodology employed present study(U-SEX-2) consistent...
Mican, Rafael; Busca Arenzana, Carmen; Vasquez, Julia; Daroca, German; Perez-Valero, Ignacio; Martin-Carbonero, Luz Author Information
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF integrase in antiretroviral-naive patients are lacking.Adult (>18 years old) human immunodeficiency virus-infected (HLA-B∗5701 negative hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally initiate or...
To analyze the efficacy and tolerability of strategy to change from rilpivirine (RPV) based regimens bictegravir / emtricitabine tenofovir alafenamide (B/F/TAF).Single-center, observational retrospective study. Patients who made B/F/TAF before February 2020 were selected, analyzing results after 24 48 weeks. The percentage that remained with an undetectable viral load was determined, as well changes in CD4 + lymphocytes, metabolic parameters renal function.A total 42 patients included....
Abstract Background Studies on switching to tenofovir alafenamide (TAF)‐based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received disoproxil fumarate (TDF) their previous regimen. This study aims evaluate changes lipid fractions, glucose, and serum markers for hepatic steatosis (HS) after from TDF‐ or TAF‐sparing regimen bictegravir/emtricitabine/TAF (B/F/TAF). Methods We performed retrospective cohort of HIV who switched B/F/TAF between...